Cevimeline 30 mg, three times daily, substantially improves saliva and tear flow in patients with Sjogren's syndrome, as well as curbs their subjective symptoms of dryness.
A 15-mg dosage of the drug relieves some symptoms and is equally well tolerated, suggests this multicentre United States study headed by Dianne Petrone from Baylor University Medical Center and Arthritis Centers of Texas, Dallas, Texas, United States.
This 12-week double-blind, randomised study sought to evaluate safety and efficacy of the two dosages of this drug for xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.
Participants were randomly assigned to receive placebo or cevimeline (15 mg or 30 mg) three times daily. They were evaluated at baseline and throughout the study for global assessment of dryness (mouth, eyes, overall) as well as subjective assessment of the specific symptoms of dry mouth and dry eyes. Researchers also measured each patient's total saliva and tear flow.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!